Business Description
Daxor Corp
NAICS : 333314
SIC : 3841
ISIN : US2394671034
Description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Beneish M-Score | 0.23 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year FCF Growth Rate | -8.3 | |||||
| 3-Year Book Growth Rate | 22.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.23 | |||||
| 9-Day RSI | 60.09 | |||||
| 14-Day RSI | 58.04 | |||||
| 6-1 Month Momentum % | -4.91 | |||||
| 12-1 Month Momentum % | 10.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6 | |||||
| Shareholder Yield % | -0.89 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Net Margin % | 64.74 | |||||
| FCF Margin % | -65.22 | |||||
| ROE % | 5.22 | |||||
| ROA % | 5.08 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 31 | |||||
| PE Ratio without NRI | 31 | |||||
| PEG Ratio | 1.69 | |||||
| PS Ratio | 17.13 | |||||
| PB Ratio | 1.38 | |||||
| Price-to-Tangible-Book | 1.38 | |||||
| EV-to-Revenue | 17.91 | |||||
| EV-to-FCF | -27.83 | |||||
| Price-to-Projected-FCF | 3.05 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.62 | |||||
| Price-to-Graham-Number | 1.38 | |||||
| FCF Yield % | -3.73 | |||||
| Forward Rate of Return (Yacktman) % | 15.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Daxor Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.375 | ||
| EPS (TTM) (€) | 0.271 | ||
| Beta | -0.23 | ||
| Volatility % | 38.3 | ||
| 14-Day RSI | 58.04 | ||
| 14-Day ATR (€) | 0.294006 | ||
| 20-Day SMA (€) | 8.485 | ||
| 12-1 Month Momentum % | 10.71 | ||
| 52-Week Range (€) | 6.45 - 9.5 | ||
| Shares Outstanding (Mil) | 4.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Daxor Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Daxor Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Daxor Corp Frequently Asked Questions
What is Daxor Corp(FRA:DX5)'s stock price today?
The current price of FRA:DX5 is €8.95. The 52 week high of FRA:DX5 is €9.50 and 52 week low is €6.45.
When is next earnings date of Daxor Corp(FRA:DX5)?
The next earnings date of Daxor Corp(FRA:DX5) is 2025-03-25 Est..
Does Daxor Corp(FRA:DX5) pay dividends? If so, how much?
Daxor Corp(FRA:DX5) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers